Piramal Pharma shares witnessed a significant jump of more than 12%, reaching their 52-week high, following the release of its strong Q2 FY25 financial results. The company’s revenue from operations grew by 17% year-on-year (YoY) to ₹2,242 crore, up from ₹1,911 crore in Q2 FY24.
In addition to revenue growth, Piramal Pharma’s EBITDA saw a healthy 28% YoY increase to ₹403 crore, improving its EBITDA margin by 150 basis points to 18%. The company also reported a remarkable 350% YoY surge in Profit After Tax (PAT), which rose to ₹23 crore, compared to ₹5 crore in the same period last year. The PAT margin stood at 1%, a significant improvement from 0% in Q2 FY24.
Piramal Pharma’s stock opened at ₹227.90, reached a high of ₹244.95, and hit a low of ₹224.05 during the day. This surge saw the stock break its 52-week high of ₹244.95, reflecting investor confidence in the company’s strong financial results.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
